autologous T cell lines reactive to nine myelin peptides

Autologous T cell lines reactive to nine myelin peptides is an investigational immunotherapy for multiple sclerosis (MS) that involves generating and expanding a patient’s own (autologous) peripheral blood-derived CD4+ or CD8+ T cells specifically reactive to nine different peptides derived from major myelin antigens—myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and proteolipid protein (PLP). These expanded anti-myelin T cells are then attenuated by irradiation and administered back into the patient as a form of “T cell vaccination” (TCV). The intended mechanism is induction of antigen-specific immune tolerance by stimulating regulatory responses or deletion/downregulation of pathogenic autoreactive effector T cells. This approach aims to reduce disease activity in MS by targeting the autoimmune response against central nervous system myelin. Clinical trials have demonstrated feasibility, safety, and preliminary efficacy in reducing relapse rates and disability progression in relapsing-progressive MS[2][3][4].

Other names

autologous anti-myelin T-cell vaccinationT cell vaccination for multiple sclerosisTCV